Diarylalkanes as potent inhibitors of binuclear enzymes

Inactive Publication Date: 2005-12-01
UNIGEN PHARM INC
View PDF4 Cites 48 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0027] In yet another embodiment, the dialkylalkanes and dialkyl alkanols can be used in the fo

Problems solved by technology

Asians and light-skinned people have lower levels of eumelanin than dark-skinned people, and correspondingly less protection against the effects of radiation.
Any compound, which interferes with the access, ligand formation, or the oxidation of monophenols at the active site of tyrosinase, will be an efficient inhibitor of tyrosinase, potentially resulting in a decrease in the production of melanin and

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diarylalkanes as potent inhibitors of binuclear enzymes
  • Diarylalkanes as potent inhibitors of binuclear enzymes
  • Diarylalkanes as potent inhibitors of binuclear enzymes

Examples

Experimental program
Comparison scheme
Effect test

Example

[0092] Example 4 describes the extraction, separation and purification of the novel diarylpropane: 1-(2-methoxy-4-hydroxyphenyl)-3-(2′-hydroxy-5′-methoxyphenyl)-propane (UP288) (1) from Broussonetia kazinoki Sieb. Et Zucc (Moraceae) (whole plant) using the general method set forth in Examples 1-3. FIG. 4 illustrates the HPLC / UV chromatogram of a HTP fraction that contains the UP288. The structure of the active compound UP288 was elucidated using a combination of spectroscopic methods as set forth in Example 4. FIG. 5 depicts the chemical structure and 13C-NMR spectrum of UP288. FIG. 6 illustrates tyrosinase inhibitory dose response curves and IC50 values for UP288 relative to kojic acid. The figure illustrates that UP288 (1) is as potent a tyrosinase inhibitor as kojic acid, having an IC50=24 μM.

[0093] Surprisingly, two similar diarylalkanes were isolated and identified from a totally different family of plant—Dianella ensifolia (L.) DC. (Liliaceae), as described in Example 5. FIG....

Example

[0094] Example 6 describes the large-scale isolation of UP302a (2), the most potent tyrosinase inhibitor, isolated from Dianella ensifolia (DE) (whole plant). With reference to Example 6, from 4.3 kg of dried biomass, a total of 30 mg of pure UP302a (2) was obtained after multiple column fractionations on silica gel, CG-161, and C-18 resins. The structure and biological function of the isolated compound were confirmed.

[0095] Due to the low natural abundance of diarylalkanes / diarylalkanols, methods to synthesize these biologically active compounds, as an alternative commercial source of this class of compounds was developed. Example 7 describes a general method for the synthesis of diarylalkanes via the reduction of substituted chalcones. For purposes of illustration the reduction of 2,4-dihydroxyphenyl)-3′,4′-dimethoxyphenylchalcone (4) to 1-(2,4-dihydroxyphenyl)-3-(3′,4′-dimethoxyphenyl)-1-propanol (5) using sodium borohydride is described. However, as set forth in Example 7, a nu...

Example

[0096] Using the general reaction described in Example 7, several other substituted diarylpropanones have been converted to diarylpropanes and / or diarylpropanols as demonstrated in Examples 8, 9 and 10. Example 11 demonstrates the synthesis of a diarylpropanol using a flavonoid glycoside isolated from a natural source as the starting material.

[0097] In another embodiment, the present invention includes methods for synthesizing this class of compounds by reaction of two appropriately substituted aromatic compounds. This embodiment is illustrated in Example 12, using the reaction of resorcinol with 3-methoxy-4-hydroxycinnamic acid for purposes of illustration. Feasible chemical reactions for synthesizing these compounds from two substituted aromatic compounds include, but are not limited to Aldol condensation between a substituted benzaldehyde and a substituted acetophenone; Claisen-Schmidt reaction or crossed aldol condensation between an aldehyde and a ketone; Grignard reaction usi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Percent by massaaaaaaaaaa
Login to view more

Abstract

The present invention implements a strategy that combines an enzyme inhibition assay with a chemical dereplication process to identify active plant extracts and the particular compounds—diarylalkanes and/or diarylalkanols within those extracts that specifically inhibit binuclear enzyme function. Included in the present invention are compositions of matter comprised of one or more of diarylalkanes and/or diarylalkanols, which inhibit the activity of binuclear enzymes, particularly tyrosinase and which prevent melanin overproduction. The present invention also provides a method for inhibiting the activity of a binuclear enzyme, particularly tyrosinase and a method for preventing and treating diseases and conditions related to binuclear enzyme function. The present invention further includes a method for preventing and treating melanin overproduction and diseases and conditions of the skin related thereto. The method for preventing and treating diseases and conditions related to binuclear enzyme function and melanin overproduction is comprised of administering to a host in need thereof an effective amount of a composition comprising one or more diarylalkanes and/or diarylalkanols synthesized and/or isolated from one or more plants together with a pharmaceutically acceptable carrier.

Description

RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Provisional Application Ser. No. 60 / 575,599, filed May 28, 2004, entitled “Diarylalkanes as Potent Inhibitors of Binuclear Enzymes,” which is incorporated herein by reference in its entirety.FIELD OF THE INVENTION [0002] This invention relates generally to the prevention and treatment of diseases and conditions mediated by binuclear enzymes. Specifically, the present invention includes a method for inhibiting the activity of an enzyme having a binuclear active site. Included in the present invention are novel compositions comprised of one or more diarylalkane(s). The diarylalkanes of the present invention can be isolated from one or more plant sources or can be obtained by organic synthesis. Further included in the present invention are methods for isolating these compounds from a natural source and methods for synthesizing these compounds. In one embodiment, the diarylalkanes are obtained by synthetic modificat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/015A61K31/05A61K31/704C07C39/15C07C39/367C07C43/23C07C45/67C07C49/835C07C215/74C07D321/12
CPCA61K31/015C07C41/32A61K31/085A61K31/09A61K31/357A61K31/40A61K31/704C07C39/15C07C39/367C07C43/23C07C45/673C07C49/835C07C215/74C07D321/12A61K31/05C07C41/26A61K8/347A61Q19/02A61K8/31A61K2800/782A61K8/9789A61K8/9794A61P1/02A61P1/12A61P1/16A61P15/00A61P15/08A61P17/00A61P17/02A61P17/16A61P17/18A61P19/02A61P19/10A61P25/00A61P25/04A61P25/08A61P25/16A61P25/20A61P25/28A61P27/02A61P29/00A61P3/00A61P3/04A61P3/12A61P31/04A61P31/10A61P31/12A61P33/06A61P35/00A61P3/06A61P37/02A61P37/04A61P37/08A61P39/06A61P43/00A61P7/06A61P9/00A61P9/10A61P9/12A61P3/10Y02A50/30A61K8/4973
Inventor JIA, QIZHAO, JI-FU
Owner UNIGEN PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products